Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
SAN DIEGO, May 30, 2013 /PRNewswire/ -- Sorrento Therapeutics (OTCBB: SRNE; or STI) today announced that Henry Ji, Ph.D., the Company's President and Chief Executive Officer, will present at the Jefferies 2013 Global Healthcare Conference on Thursday, June 6th, 2013, at 3:00 PM ET. The conference will be held at the Grand Hyatt in New York, NY.
A live webcast of the presentation will be available at the start time of the presentation by accessing http://wsw.com/webcast/jeff77/srne/. Following the live presentation, a replay of the webcast will be available for 90 days.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company focused on the acquisition, discovery, development and commercialization of novel and proprietary biotherapeutics for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic and infectious diseases. STI's objective is to identify drug development candidates derived from its proprietary human antibody libraries and, either independently or through partnerships, advance selected targets into preclinical or clinical development. In 2012, STI identified and further developed a number of potential drug product candidates across various therapeutic areas. STI intends to select several lead product candidates to progress into preclinical development activities in 2013, including human anti-PD-L1 and anti-PD-1 monoclonal antibodies (mAbs) that have demonstrated strong immunomodulatory activity in vitro comparable to competitor mAbs currently in clinical development as well as significant anti-cancer activity in a tumor mouse model.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the preclinical and clinical development of STI's human antibody therapeutics. All such forward-looking statements are based on STI's current beliefs and expectations, and should not be regarded as a representation by STI that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in STI's businesses; the scope and validity of patent protection for STI's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that STI may require substantial additional funding in order to obtain regulatory approval for and commercialize quorum quenching technologies or any other product; and additional risks set forth in Sorrento Therapeutics' filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento Therapeutics' judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and STI undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SOURCE Sorrento Therapeutics, Inc.